Latency intervals after first cytotoxic therapy to first bone marrow dysfunction according to exposure to specific classes of chemotherapy or radiation therapy
Therapeutic agent . | No. patients . | Median latency, mo . | IQR, mo . | Range, mo . | P . |
|---|---|---|---|---|---|
| Alkylator | |||||
| Yes | 236 | 61 | 36-106 | 3-524 | .72 |
| No | 52 | 62 | 26-114 | 10-626 | |
| Topoisomerase 2 inhibitor | |||||
| Yes | 112 | 63 | 34-98 | 9-396 | .53 |
| No | 175 | 60 | 37-115 | 3-626 | |
| Antimetabolite | |||||
| Yes | 92 | 66 | 35-106 | 3-265 | .81 |
| No | 194 | 60 | 35-112 | 9-626 | |
| Antitubulin | |||||
| Yes | 155 | 66 | 40-107 | 9-396 | .14 |
| No | 132 | 54 | 28-108 | 3-626 | |
| RT | |||||
| Yes | 177 | 67 | 39-107 | 10-626 | .08 |
| No | 116 | 53 | 33-106 | 3-238 |
Therapeutic agent . | No. patients . | Median latency, mo . | IQR, mo . | Range, mo . | P . |
|---|---|---|---|---|---|
| Alkylator | |||||
| Yes | 236 | 61 | 36-106 | 3-524 | .72 |
| No | 52 | 62 | 26-114 | 10-626 | |
| Topoisomerase 2 inhibitor | |||||
| Yes | 112 | 63 | 34-98 | 9-396 | .53 |
| No | 175 | 60 | 37-115 | 3-626 | |
| Antimetabolite | |||||
| Yes | 92 | 66 | 35-106 | 3-265 | .81 |
| No | 194 | 60 | 35-112 | 9-626 | |
| Antitubulin | |||||
| Yes | 155 | 66 | 40-107 | 9-396 | .14 |
| No | 132 | 54 | 28-108 | 3-626 | |
| RT | |||||
| Yes | 177 | 67 | 39-107 | 10-626 | .08 |
| No | 116 | 53 | 33-106 | 3-238 |